VolitionRx Relocates HQ, Adjusts Fiscal Year End
Ticker: VNRX · Form: 8-K · Filed: Dec 11, 2025 · CIK: 93314
Sentiment: neutral
Topics: corporate-actions, filing-update
Related Tickers: VNRX
TL;DR
VNRX moved its HQ to Henderson, NV and changed its fiscal year end.
AI Summary
VolitionRx Limited announced on December 5, 2025, a change in its principal executive offices to 1489 West Warm Springs Road, Suite 110, Henderson, Nevada 89014. The company also reported a change in its fiscal year end to December 31st. This 8-K filing also indicates potential changes related to directors, officers, and compensatory arrangements.
Why It Matters
A change in principal executive offices and fiscal year end can signal operational shifts or strategic realignments within the company.
Risk Assessment
Risk Level: low — The filing primarily concerns administrative changes like office relocation and fiscal year adjustments, with no immediate financial or operational risks apparent.
Key Players & Entities
- VolitionRx Limited (company) — Registrant
- Henderson, Nevada (location) — New Principal Executive Offices
- December 5, 2025 (date) — Date of earliest event reported
- December 31 (date) — Fiscal Year End
FAQ
What is the new address for VolitionRx Limited's principal executive offices?
The new address is 1489 West Warm Springs Road, Suite 110, Henderson, Nevada 89014.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on December 5, 2025.
What is VolitionRx Limited's new fiscal year end?
VolitionRx Limited's fiscal year end is now December 31st.
What other items are indicated in this 8-K filing besides the office change and fiscal year end?
The filing indicates potential changes related to the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements of certain officers.
In which state is VolitionRx Limited incorporated?
VolitionRx Limited is incorporated in Delaware.
Filing Stats: 519 words · 2 min read · ~2 pages · Grade level 14.1 · Accepted 2025-12-11 17:00:30
Key Financial Figures
- $0.001 — ich Registered Common Stock, par value $0.001 per share VNRX NYSE American, LLC
Filing Documents
- vnrx_8k.htm (8-K) — 23KB
- 0001477932-25-008932.txt ( ) — 134KB
- vnrx-20251205.xsd (EX-101.SCH) — 5KB
- vnrx-20251205_lab.xml (EX-101.LAB) — 14KB
- vnrx-20251205_cal.xml (EX-101.CAL) — 1KB
- vnrx-20251205_pre.xml (EX-101.PRE) — 9KB
- vnrx-20251205_def.xml (EX-101.DEF) — 2KB
- vnrx_8k_htm.xml (XML) — 4KB
From the Filing
vnrx_8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 5, 2025 VolitionRx Limited (Exact name of registrant as specified in its charter) Delaware 001-36833 91-1949078 (State or other jurisdiction (Commission (IRS Employer of Incorporation) File Number) Identification Number) 1489 West Warm Springs Road , Suite 110 Henderson , Nevada 89014 (Address of principal executive offices and zip code) +1 ( 512 ) 774-8930 (Registrant's telephone number, including area code) Not Applicable (Former name or former address, if changed from last report.) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of Each Class Trading Symbol(s) Name of Each Exchange on which Registered Common Stock, par value $0.001 per share VNRX NYSE American, LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On December 5, 2025, Volition Veterinary Diagnostics Development, LLC ("Volition Veterinary"), a majority-owned subsidiary of VolitionRx Limited (the "Company"), provided notice of termination of its employment agreement with Dr. Salvatore Thomas Butera, the Chief Executive Officer of Volition Veterinary, effective as of January 31, 2026 (the "Termination Date"). The decision to end Dr. Butera's employment was made for operational reasons and not as a result of any disagreement or dispute with the Company on any matter relating to the Company's operations, policies or practices. Effective January 31, 2026, Volition Veterinary will eliminate the Chief Executive Officer position as part of the Company's ongoing cost-realignment efforts. Dr. Butera's duties will be redistributed within the Company. Following the Termination Date, it is intended that Dr. Butera will remain with Volition Veterinary on a part-time consulting basis, providing advisory services, subject to mutually agreed upon terms. 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. VOLITIONRX LIMITED Date: December 11, 2025 By: /s/ Cameron Reynolds Cameron Reynolds Chief Executive Officer & President 3